000250 — Sam Chun Dang Pharm Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩3tn
- KR₩3tn
- KR₩193bn
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Interim Report | Interim Report | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 99,709 | 96,966 | 97,025 | 86,248 | 92,744 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 38,900 | 36,540 | 38,589 | 39,004 | 35,111 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 162,493 | 166,528 | 168,920 | 157,749 | 163,906 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 57,334 | 63,276 | 74,112 | 87,212 | 90,009 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 290,151 | 317,079 | 345,997 | 372,793 | 408,022 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 45,206 | 23,658 | 54,081 | 38,160 | 57,957 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 132,279 | 130,453 | 171,902 | 199,052 | 187,523 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 157,872 | 186,626 | 174,095 | 173,741 | 220,499 |
Total Liabilities & Shareholders' Equity | 290,151 | 317,079 | 345,997 | 372,793 | 408,022 |
Total Common Shares Outstanding |